Some pivotal advances in MDS/AML management have been voluntarily not discussed in this article, more particularly concerning druggable mutations, such as FLT3, IDH1 or IDH2, since they have been extensively reviewed. This evidence concerns the gene IDH1 and acute myeloid leukemia.